3种方案治疗乳腺增生药物经济学分析  

Analysis of Pharmacoeconomics of Three Chemotherapy Regimens for Hyperplasia of Mammary Gland

作　　者：季屹红[1] 张锦林[1] 沈飚[1] 

机构地区：[1]南通大学附属肿瘤医院,南通市226361

出　　处：《中国医院用药评价与分析》2010年第2期152-153,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨乳腺增生不同用药方案的临床疗效和经济学效果。方法:选择乳腺增生患者90例,随机分成3组,口服新癀片(A组)、小金丸+他莫昔芬片(B组)、乳宁颗粒+他莫昔芬片(C组)进行治疗。运用药物经济学的成本-效果分析方法进行分析评价。结果:治疗总成本A组为309.40元、B组为1435.20元、C组为749.20元,总有效率分别为A组56.7%、B组90.0%、C组86.7%。每获得1个单位效果,3组方案所需成本分别为5.46元、15.95元和8.64元,在A组方案的基础上,每增加1个单位效果,B组和C组所追加的成本分别为33.81元和14.66元。结论:乳宁颗粒+他莫昔芬片方案为最佳治疗方案。OBJECTIVE：To study the clinical efficacy and economic effectiveness of three chemotherapy regimens in the treatment of hyperplasia of mammary gland. METHODS： A total of 90 patients with hyperplasia of mammary gland were randomized to 3 groups： Group A （Xinhuang tablets）,Group B （Xiaojin pill plus Tamoxifen tablets） and Group C （Runing granules plus Tamoxifen tablets）. The three regimes were evaluated using cost-effectiveness analysis in pharmacoeconomics. RESULTS： In group A,B and C,the total treatment costs were 309.40,1 435.20 and 749.20 Yuan,respectively and the total effective rates were 56.7 %,90.0 % and 86.7%,respectively. The costs for obtaining each unit of effectiveness in Group A,B and C were 5.46,15.95 and 8.64 Yuan,respectively. As against Group A,the incremental cost for each unit increment of effectiveness was 33.81Yuan in Group B and 14.66 Yuan in Group C. CONCLUSION： Group C is the preferable chemotherapy regimen for hyperplasia of mammary gland in terms of cost-effectiveness.

关 键 词：乳腺增生 药物经济学 成本-效果分析 

分 类 号：R932[医药卫生—生药学]